Complete Conference Coverage Archive
A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.
Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.
Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.
The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.
Researchers sought to determine if maintenance treatment with metronomic chemotherapy would improve survival outcomes in rhabdomyosarcoma.
Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26
The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.
Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.
When variables such as age and serious medical conditions were accounted for cancer versus non-cancer mortality was two times higher for women compared with men.
SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer
Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.
It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.
MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy
With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.
Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.
Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.
Immune-Related Adverse Events During Anti-PD-1 Therapy May Increase Survival in Head and Neck Cancer
It is believed that immune competence may modify anti-tumor response with anti-PD-1 therapy.
Two year treatment with pembrolizumab prolonged overall survival compared with standard of care among patients with HNSCC, but the effects on quality of life require further elucidation.
With precision medicine nearly 23% of all patients who present with advanced lung cancer are treated with FDA- or EMA-approved targeted therapies or immunotherapies instead of chemotherapy.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
Researchers sought to determine if the addition of nivolumab to radiotherapy and chemotherapy could improve outcomes among this patient population.
Although the addition of stereotactic body radiation therapy (SBRT) to nivolumab did not increase toxicity, it did not lead to any improvement in response rates or survival outcomes among patients with metastatic head and neck squamous cell carcinoma (HNSCC).
Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma
The increase in use of lenalidomide as maintenance treatment emphasizes the need to explore additional treatment options among patients with lenalidomide-refractory multiple myeloma.
Researchers randomly assigned 559 patients with relapsed/refractory multiple myeloma to receive bortezomib and dexamethasone with or without pomalidomide.
Symptom Assessment Intervention Led by Lay Health Workers Improved Patient Satisfaction and Reduced Health Care Use and Costs
Lay health workers used phone calls to assess symptoms on a weekly basis for high-risk patients and on a monthly basis for low-risk patients.
Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.
The researchers also developed novel emoji PRO scales and associations between PROs and wearable data.
Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.
The impact of this attenuated-dose hypomethylating agents among patients with low-risk myelodysplastic syndrome who are transfusion independent requires further investigation.
Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.
The efficacy of nelarabine among newly diagnosed patients with T-cell ALL has not been fully explored.
Current literature reflects estimates, but not actual rates, of low-dose computed tomography adherence across the United States.
Investigators sought to determine whether cognitive behavioral therapy or acupuncture was more effective in addressing insomnia in this population.
The CYCORE system may enable physicians to intervene at the early signs of dehydration and other radiotherapy-associated symptoms.
The total morphine equivalents used were, however, not significantly different between arms.
These findings were, however, significant only in states that expanded Medicaid eligibility.
The number of PCA attempts did not differ between treatment arms.
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
Approximately 50% and 30% of patients with late- and early-stage disease, respectively, undergo surgery without adjuvant therapy.
The benefit of adjuvant radiotherapy in this setting was previously unestablished.
The mean total opioid morphine equivalent use in the celecoxib arm was 31.8 mg vs 45 mg in the control arm.
Check-Mate 141 Results: Nivolumab Improved OS in Patients With Recurrent or Metastatic Head and Neck Cancer
Not all patients who received nivolumab, however, had improved PFS.
Doses of at least 60 mg yielded tumor reductions of 2% to 70% among 25 of the 30 evaluated patients.
At the time of final analysis, 192 of 302 patients had died.
One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.
Improvement in RFS was seen regardless of PD-L1 status.
Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Antigen-specific T cells increased in frequency in vaccinated mice.
Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.
p53 mutational status may be a viable strategy upon which to base the course of therapy.
There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.
Nearly half of patients were denied insurance coverage for a recommended treatment.
Toxicity was similar in both arms.
Patients in the single-course MTX+ACTD arm had a 46.81% CR rate after initial therapy.
Researchers randomly assigned 120 patients to receive bupivacaine HCl or liposomal bupivacaine.
Overall, 257 vs 527 SLNs were detected by isosulfan blue vs ICG, respectively.
There were no reported changes in pain scores after surgery.
Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.
The impact of the ACA on health insurance access among women diagnosed with a gynecologic cancer was previously unestablished.
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.
The impact of this treatment on quality of life was not previously reported.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
The median follow-up was 17.6 months at time of interim analysis.
Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.
Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.
A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.
It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.
Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.
Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.
MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.
Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.
Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.
Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.
Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve survival among patients with metastatic pancreatic adenocarcinoma.
The study arms had similar rates of adverse events, with 34.7% of patients in the cisplatin arm and 31.2% of patients in the S-1 arm reporting clinically relevant events.
Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy may be a lower-cost alternative, with better post-operative outcomes, to open transthoracic esophagectomy.
Previous research suggested that EIPL may improve survival by reducing the number of intraperitoneal-free cancer cells.
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
Dr Dreyling, professor of medicine at the University of Munich Hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL.
The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.
Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.
Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.
Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.
Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.
Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.
The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.
A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Coffee and Cancer
- Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC
- Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia
- Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma
- In Melanoma, Older Adults Could Benefit More From Treatment with PD-1 Inhibitors
- JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas
- Coffee and Cancer
- Pembrolizumab FDA-Approved for the Treatment of Advanced Cervical Cancer
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC